Abstract:We discuss the issue of identifiability of models for multiple dichotomous diagnostic tests in the absence of a gold standard (GS) test. Data arise as multinomial or product-multinomial counts depending upon the number of populations sampled. Models are generally posited in terms of population prevalences, test sensitivities and specificities, and test dependence terms. It is commonly believed that if the degrees of freedom in the data meet or exceed the number of parameters in a fitted model then the model is… Show more
“…Therefore, the data violate the conditional independence assumption of standard latent class analysis, and require the use of a recently developed latent class analysis model based on Bayesian methods that allow for conditional dependence among multiple test results by relying on surgeon estimation of plausible dependencies between test results [21]. Johnson et al [20] provided Bayesian methods for the Hui-Walter model and Dendukuri and Joseph [12] extended the model to incorporate two additional dependence parameters (one for each latent class), in the case of two diagnostic tests.…”
“…Therefore, the data violate the conditional independence assumption of standard latent class analysis, and require the use of a recently developed latent class analysis model based on Bayesian methods that allow for conditional dependence among multiple test results by relying on surgeon estimation of plausible dependencies between test results [21]. Johnson et al [20] provided Bayesian methods for the Hui-Walter model and Dendukuri and Joseph [12] extended the model to incorporate two additional dependence parameters (one for each latent class), in the case of two diagnostic tests.…”
“…Jones et al (2010) proposed that in the construction of conditional dependence models, mainly simple extensions of the conditional independence model should be considered. Essentially, in the first set of simple parameterizations, the conditional dependence between iELISA and RBT, between iELISA and SAT and between RBT and SAT were each added in turn to the conditional independence model.…”
a b s t r a c tThe true prevalence of brucellosis and diagnostic test characteristics of three conditionally dependent serological tests were estimated using the Bayesian approach in goats and sheep populations of Bangladesh. Serum samples from a random selection of 636 goats and 1044 sheep were tested in parallel by indirect ELISA (iELISA), Rose Bengal Test (RBT) and Slow Agglutination Test (SAT). The true prevalence of brucellosis in goats and sheep were estimated as 1% (95% credibility interval (CrI): 0.7-1.8) and 1.2% (95% CrI: 0.6-2.2) respectively. The sensitivity of iELISA was 92.9% in goats and 92.0% in sheep with corresponding specificities of 96.5% and 99.5% respectively. The sensitivity and specificity estimates of RBT were 80.2% and 99.6% in goats and 82.8% and 98.3% in sheep. The sensitivity and specificity of SAT were 57.1% and 99.3% in goats and 72.0% and 98.6% in sheep. In this study, three conditionally dependent serological tests for the diagnosis of small ruminant brucellosis in Bangladesh were validated. Considerable conditional dependence between IELISA and RBT and between RBT and SAT was observed among sheep. The influence of the priors on the model fit and estimated parameter values was checked using sensitivity analysis. In multiple test validation, conditional dependence should not be ignored when the tests are in fact conditionally dependent.
“…In the more general case, with the two distributions being modeled nonparametrically, even the assumption of stochastic domination of one distribution over the other does not make the model identifiable. Moreover, in the area of medical classification with multiple binary tests, it is often the case that models either lack identifiability or require potentially strong assumptions in order to guarantee identifiability [21,22]. The approach taken here buys identifiability based on having additional information, including continuous test outcomes instead of dichotomous outcomes and covariate information that should be helpful in mitigating the lack of a gold standard.…”
A novel semiparametric regression model is developed for evaluating the covariate-specific accuracy of a continuous medical test or biomarker. Ideally, studies designed to estimate or compare medical test accuracy will use a separate, flawless gold-standard procedure to determine the true disease status of sampled individuals. We treat this as a special case of the more complicated and increasingly common scenario in which disease status is unknown because a gold-standard procedure does not exist or is too costly or invasive for widespread use. To compensate for missing data on disease status, covariate information is used to discriminate between diseased and healthy units. We thus model the probability of disease as a function of 'disease covariates'. In addition, we model test/biomarker outcome data to depend on 'test covariates', which provides researchers the opportunity to quantify the impact of covariates on the accuracy of a medical test. We further model the distributions of test outcomes using flexible semiparametric classes. An important new theoretical result demonstrating model identifiability under mild conditions is presented. The modeling framework can be used to obtain inferences about covariate-specific test accuracy and the probability of disease based on subject-specific disease and test covariate information. The value of the model is illustrated using multiple simulation studies and data on the age-adjusted ability of soluble epidermal growth factor receptor -a ubiquitous serum protein -to serve as a biomarker of lung cancer in men. sas code for fitting the model is provided.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.